NANOGP2

Across TCGA pan-cancer cohorts, NANOGP2 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of NANOGP2’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where NANOGP2 RNA is repressed in tumor relative to normal tissue. In most cancer types NANOGP2 is over-expressed in tumor, although a few such as LUSC and KIRP show the opposite, repressed pattern.

LUSC, KIRP, and BRCA are the cancer types where NANOGP2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NANOGP2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUSC	Male	All	−0.139	.003	5	view →
KIRP	All	All	−0.040	.007	4	view →
BRCA	All	III,IV	+0.023	.018	4	view →
KICH	All	All	−0.042	.004	3	view →
THCA	All	All	−0.056	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

NANOGP2–LUSC

Open the LUSC breakdown →